Lantheus Holdings Inc (LNTH) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.

Total Assets Chart for Lantheus Holdings Inc

Lantheus Holdings Inc (LNTH) total assets for FY2025 were USD 2.2B, a 12.5% change from FY2024. Lantheus Holdings Inc's total assets grew from USD 324.7M in 2012 to USD 2.2B in 2025 (586.1% over 13 years). Total assets compound annual growth rate: 5-year CAGR of 20.7%, 10-year CAGR of 24.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$6.53B
Implied Share Price
$99.95
Enterprise Value
$6.56B
Revenue (TTM)
$1.56B
EBITDA
$392.22M
Profit Margin
17.69%
Trailing P/E
24.20
Forward P/E
14.27
Price/Book (MRQ)
4.98
Price/Sales (TTM)
4.19
EV/EBITDA
13.92
EV/Revenue
4.22
Dividend Yield
—
Book Value
$20.10
Free Cash Flow (FY2025)
$354.05M
Free Cash Flow Yield
5.42%

Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.